BURLINGTON, Mass. and CAMBRIDGE, Mass., July 18, 2019 /PRNewswire/ — MilliporeSigma and the Broad Institute of MITand Harvard today announced an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for use in commercial research and product development. “Together with the Broad Institute, we are simplifying the path to licensing CRISPR technology, which will make it more widely available to the global research and…
Read More
The 2019 Warren Alpert Foundation Prize has been awarded to four scientists for pioneering work in the field of optogenetics, a revolutionary technique that uses light and genetic modification to control the activity of cells in the brain. Optogenetics holds promise not only for unraveling some of the brain’s more confounding mysteries, including decision-making and behavior, but also for elucidating and manipulating…
Read More
Series A Round Led by Vida Ventures and Omega Funds Company Platform Using Small Molecule Microarray (SMM) Technology has the Potential to Unlock Historically Undruggable Targets July 18, 2019 06:00 AM Eastern Daylight Time SAN MATEO, Calif. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Kronos Bio, Inc. (Kronos), a Two River portfolio company, today announced it has closed a $105 million Series A Preferred…
Read More
Award honors outstanding scientists and engineers beginning their independent research careers By Lindsay Brownell (CAMBRIDGE, Mass.) — Earlier this month, President Donald J. Trump announced that Wyss Core Faculty member Conor Walsh, Ph.D. is among this year’s recipients of the Presidential Early Career Award for Scientists and Engineers (PECASE). The PECASE is the highest honor bestowed by the United States Government on outstanding…
Read More
In the wake of reports of CRISPRed babies born in China, a bipartisan resolution “opposes the experiments that resulted in pregnancies using genome-edited human embryos.” Senators Dianne Feinstein (D-CA), Marco Rubio (R-FL), and Jack Reed (D-RI) introduced a resolution yesterday (July 15) calling for global collaboration in developing guidelines for the use of gene editing technologies in the context of…
Read More
Woburn-based hearing loss startup Frequency Therapeutics has found its first partner, but it will give up most of its commercial rights in a deal announced this week. Japanese firm Astellas Health will join Frequency Therapeutics as it steers its first treatment for the most common cause of hearing loss through the clinic. In exchange for $80 million upfront and a…
Read More
As cancer cells progress, they accumulate hundreds and even thousands of genetic and epigenetic changes, resulting in protein expression profiles that are radically different from that of healthy cells. But despite their heavily mutated proteome, cancer cells can evade recognition and attack by the immune system. Immunotherapies, particularly checkpoint inhibitors that reinvigorate exhausted T cells, have revolutionized the treatment of…
Read More
BOSTON – Higher levels of daily physical activity may protect against the cognitive decline and neurodegeneration (brain tissue loss) from Alzheimer’s disease (AD) that alters the lives of many older people, researchers from Massachusetts General Hospital (MGH) have found. In a paper in JAMA Neurology, the team also reported that lowering vascular risk factors may offer additional protection against Alzheimer’s and…
Read More
A new study published in Cell Reports found that a transcription factor called Slug serves as ‘command central’ for determining breast stem cell health, regulating both stem cell activity and repair of DNA damage. The research team also discovered that Slug likely functions as a safeguard against age-related decline of breast stem cell function. Transcription factors are proteins that bind…
Read More
Cambridge, Massachusetts-based Neon Therapeutics announced top-line results in its Phase Ib clinical trial of NEO-PV-01, its personal neoantigen vaccine candidate. NEO-PV-01 was being evaluated in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) in advanced or metastatic melanoma, smoking-associated non-small cell lung cancer (NSCLC) and bladder cancer. In all three cancer types, data showed prolonged and consistent improvements in progression-free survival (PFS) that is similar…
Read More